TripleFive Pilot Study investigating the feasibility and initial safety of the application of the haemostatic sponge ACF-Matrix haemostat in 10 Coronary Artery Bypass Grafting patients.

1. Patients 18 years or older;

2. Patients demonstrating signs and symptoms of coronary ischaemia and/or stenosis clinically considered suitable for correction by CABG surgery;

3. Investigator is satisfied that there are no other physical conditions present which would prevent the patient from entering and completing the Study;

4. Patients who are willing to participate in the proposed Study as evidenced by signing an informed consent form.

1. Patients coming in for an emergency CABG procedure;

2. Patients coming in for a re- CABG procedure;

3. Patients participating in another clinical trial;

4. Patients showing clinical signs of local or systemic infection, requiring (immediate intravenous) treatment with antibiotics;

5. Patients suffering from blood coagulation disorders;

6. Known presence of any disease or medical condition which may affect the wound healing process of the target wound (e.g. malignancy, vasculitis, connective tissue disease, immunological disorder);

7. A very poor life expectancy of less than 12 weeks, according to the investigator’s judgement;

8. Known allergy to porcine products;

9. Any physical or mental state that precludes ability to abide by Study criteria;

10. Patients not able to give consent, subsequent to initial informed consent;

11. The patient is pregnant or a nursing mother;

12. Evidence of chronic alcohol or drug abuse.